Regulation of human gonadotropins

Gynecol Invest. 1970;1(3):169-78. doi: 10.1159/000301943.

Abstract

PIP: Serum LH (luteinizing hormone), FSH (follicle-stimulating hormone), and progesterone concentrations and urinary pregnanediol excretion were evaluated in 10 women before, during, and after chlomadinone therapy. 5 received .5mg continuously for 51-60 days; 5 received .5mg continuously for at least 6 months. A typical midcycle surge of LH and FSH was not found on any of the 5 short-term subjects during the treatment cycles. 4 of the 5 women showed a typical, mutiple elevations of the baseline concentrations of LH without concomitant rises in FSH. Pregnanediol excretion levels were low on 3 out of 5 women. 1 woman had relatively normal luteal phase progesterone in the first treatment cycle, and 2 in the second. All parameters reverted to normal patterns after withdrawal of the drug. In the long-term group, most women showed an increase in gonadotropin concentration; increased concentrations of FSH were more marked in subjects in the long-term study and progesterone levels reached 16 ng/ml.

MeSH terms

  • Acetates / administration & dosage
  • Administration, Oral
  • Body Temperature
  • Chlormadinone Acetate / administration & dosage*
  • Chlormadinone Acetate / pharmacology
  • Female
  • Follicle Stimulating Hormone / blood*
  • Humans
  • Luteinizing Hormone / blood*
  • Menstruation / drug effects
  • Ovulation / drug effects
  • Pregnanediol / urine
  • Progesterone / blood*
  • Time Factors

Substances

  • Acetates
  • Chlormadinone Acetate
  • Progesterone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Pregnanediol